Journal of International Oncology››2021,Vol. 48››Issue (7): 402-408.doi:10.3760/cma.j.cn371439-20201105-00077
• Original Articles •Previous ArticlesNext Articles
Wang Qian1, Tan Xiaojun1, Zhang Donghui1, Luo Kai2()
Received:
2020-11-05Revised:
2021-01-08Online:
2021-07-08Published:
2021-07-26Contact:
Luo Kai E-mail:luokainan@126.comSupported by:
Wang Qian, Tan Xiaojun, Zhang Donghui, Luo Kai. Application of β-catenin, Cyclin D1 and DKK1 in pathologically aided diagnosis of breast cancer[J]. Journal of International Oncology, 2021, 48(7): 402-408.
[1] | Youlden DR, Baade PD, Walker R, et al. Breast cancer incidence and survival among young females in Queensland, Australia[J]. J Adolesc Young Adult Oncol, 2020, 9(3):402-409. DOI: 10.1089/jayao.2019.0119. doi:10.1089/jayao.2019.0119 |
[2] | Zuo TT, Zheng RS, Zeng HM, et al. Female breast cancer incidence and mortality in China, 2013[J]. Thorac Cancer, 2017, 8(3):214-218. DOI: 10.1111/1759-7714.12426. doi:10.1111/tca.2017.8.issue-3 |
[3] | Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer[J]. Int J Biol Sci, 2017, 13(11):1387-1397. DOI: 10.7150/ijbs.21635. doi:10.7150/ijbs.21635 |
[4] | Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer[J]. Crit Rev Oncol Hematol, 2016, 99:141-149. DOI: 10.1016/j.critrevonc.2015.12.005. doi:10.1016/j.critrevonc.2015.12.005 |
[5] | Li K, Zhang J, Tian Y, et al. The Wnt/β-catenin/VASP positive feedback loop drives cell proliferation and migration in breast cancer[J]. Oncogene, 2020, 39(11):2258-2274. DOI: 10.1038/s41388-019-1145-3. doi:10.1038/s41388-019-1145-3 |
[6] | Rattanaburee T, Tipmanee V, Tedasen A, et al. Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation[J]. Biomed Pharmacothe, 2020, 129:110361. DOI: 10.1016/j.biopha.2020.110361. |
[7] | Huang J, Lu T, Kuang W. Prognostic role of dickkopf-1 in patients with cancer[J]. Medicine, 2020, 99(21):e20388. DOI: 10.1097/MD.0000000000020388. doi:10.1097/MD.0000000000020388 |
[8] | 曹亮. 免疫组化五项指标(PSA、PAP、HCK、P63、AMACR)的表达在前列腺病变诊断中的应用价值[D]. 长沙: 中南大学, 2010. DOI: 10.7666/d.y1720743. |
[9] | 陈冬华, 李强, 周浩, 等. 上海市农村妇女乳腺疾病谱及影响因素研究[J]. 中国初级卫生保健, 2013, 27(12):48-49. DOI: 10.3969/j.issn.1001-568X.2013.12.0018. |
[10] | Liu S, Wang Z, Liu Z, et al. miR-221/222 activate the Wnt/β-catenin signaling to promote triple negative breast cancer[J]. J Mol Cell Biol, 2018, 10(4):302-315. DOI: 10.1093/jmcb/mjy041. doi:10.1093/jmcb/mjy041 |
[11] | Taciak B, Pruszynska I, Kiraga L, et al. Wnt signaling pathway in development and cancer[J]. J Physiol Pharmacol, 2018, 69(2):185-196. DOI: 10.26402/jpp.2018.2.07. doi:10.1139/y91-027 |
[12] | Shang S, Hua F, Hu ZW. The regulation of β-catenin activity and function in cancer: therapeutic opportunities[J]. Oncotarget, 2017, 8(20):33972-33989. DOI: 10.18632/oncotarget.15687. doi:10.18632/oncotarget.v8i20 |
[13] | 杨红敏. 乳腺癌中Wnt信号通路关键因子β-catenin的突变和表达研究[J]. 数理医药学杂志, 2019, 32(8):1124-1126. DOI: 10.3969/j.issn.1004-4337.2019.08.008. |
[14] | Pandey A, Bahl C, Sharma S, et al. Functional role of CyclinD1 polymorphism (G870A) in modifying susceptibility and overall survival of North Indian lung cancer patients[J]. Tumori, 2018, 104(3):179-187.DOI: 10.1177/0300891617753477. doi:10.1177/0300891617753477 |
[15] | Feng ZY, Xu XH, Cen DZ, et al. miR-590-3p promotes colon cancer cell proliferation via Wnt/β-catenin signaling pathway by inhibiting WIF1 and DKK1[J]. Eur Rev Med Pharmacol Sci, 2017, 21(21):4844-4852. |
[16] | Ni D, Yi Q, Liu J, et al. A1CF-promoted colony formation and proliferation of RCC depends on DKK1-MEK/ERK signal axis[J]. Gene, 2020, 730:144299. DOI: 10.1016/j.gene.2019.144299. doi:10.1016/j.gene.2019.144299 |
[17] | 陆鸿略, 张淑君, 岳文慧, 等. Dkk-1及Bcl-2蛋白在人鼻腔鼻窦鳞状细胞癌中的表达及意义[J]. 重庆医学, 2015, 44(12):1652-1654, 1657. DOI: 10.3969/j.issn.1671-8348.2015.12.023. |
[18] | 潘理会, 李春辉, 佟晓波, 等. Wnt信号通路的组件蛋白DKK-1、β-catenin及CyclinD1在胃癌中的表达与相互关系[J]. 实用医学杂志, 2013, 29(15):2517-2519. DOI: 10.3969/j.issn.1006-5725.2013.15.037. |
[19] | Ren L, Chen H, Song J, et al. MiR-454-3p-mediated Wnt/β-catenin signaling antagonists suppression promotes breast cancer metastasis[J]. Theranostics, 2019, 9(2):449-465. DOI: 10.7150/thno.29055. doi:10.7150/thno.29055 |
[20] | Zhuang X, Zhang H, Li X, et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1[J]. Nat Cell Biol, 2017, 19(10):1274-1285. DOI: 10.1038/ncb3613. doi:10.1038/ncb3613 |
[1] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[3] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[4] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[5] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[6] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[7] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[8] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[9] | Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[10] | Wu Minhang, Sun Wenzheng, Yu Qingzhuo, Guo Rong, Ye Hui, Du Ying, Qiu Jin, An Huazhang, Cao Lili.RNF43 inhibits PD-L1 expressionviaβ-catenin in melanoma cells and promotes CD8+T cell-mediated anti-tumor immune reaction[J]. Journal of International Oncology, 2023, 50(7): 407-412. |
[11] | Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[12] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[13] | Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240. |
[14] | Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149. |
[15] | Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||